Replies to post #51724 on Biotech Values

[DewDiligence]

>…Avastin is a smaller protein, thus potentially slightly more capable of crossing the retinal-blood barrier, but the chance of it getting into the bloodstream in sufficient quantity to do harm elsewhere is almost nil, in my humble opinion.<

Lucentis is smaller: about one-third the size of Avastin.

>raises the question of why Avastin is so much cheaper to produce on the scale needed to treat AMD…<

Gram for gram, Lucentis is cheaper to produce than Avastin because it is made using E. coli.

>why [Avastin] couldn't be packaged in smaller single use vials for AMD thus eliminating the "compounding" issues.<

If DNA did that, then they would be legally liable for any problems. The FDA might also question why DNA wanted to make a dose suitable only for an off-label use!

[masterlongevity]

"Yes, Avastin is a smaller protein, thus potentially slightly more capable of crossing the retinal-blood barrier"


Based on early studies conducted,
Avastin is too large to fully penetrate the retina. (pre-clincial), but Lucentis is not